Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABFRA:3XV -2.64%89 EV-to-FCF is 47.01 as of Jul. 14, 2026, which is 60% below its 10-year median of 116.77. GuruFocus rates FRA:3XV with a GF Score™ of 89/100 and a GF Value™ of €36.59 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 416 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 74.76% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xvivo Perfusion AB's Enterprise Value is €786.30 Mil.
Xvivo Perfusion AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €16.73 Mil. Therefore, Xvivo Perfusion AB's EV-to-FCF for today is 47.01.
The historical rank and industry rank for Xvivo Perfusion AB's EV-to-FCF or its related term are showing as below:
FRA:3XV'
s EV-to-FCF Range Over the Past 10 Years
Min: -943.17 Med: 116.77 Max: 3532
Current: 47.74
During the past 13 years, the highest EV-to-FCF of Xvivo Perfusion AB was 3532.00. The lowest was -943.17. And the median was 116.77.
FRA:3XV's EV-to-FCF is ranked worse than 74.76% of 416
companies
in the Medical Devices & Instruments industry
Industry Median: 23.305
vs FRA:3XV: 47.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xvivo Perfusion AB (FRA:3XV) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xvivo Perfusion AB's PE Ratio (TTM) for today is calculated as:
Xvivo Perfusion AB's share price for today is €25.08.
Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.218.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xvivo Perfusion AB EV-to-FCF Related Terms
Xvivo Perfusion AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's EV-to-FCF falls into.
Xvivo Perfusion AB's current Enterprise Value is €786.30 Mil.
Xvivo Perfusion AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.73 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (FRA:3XV) has a EV-to-FCF of 47.01 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xvivo Perfusion AB and its competitors. This is 60% below median its historical median of 116.77. According to the industry distribution chart, Xvivo Perfusion AB ranks #311 out of 416 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is Xvivo Perfusion AB's EV-to-FCF too high?
Xvivo Perfusion AB's current EV-to-FCF of 47.01 is 60% below median its 10-year median of 116.77. The Medical Devices & Instruments industry median EV-to-FCF is 23.31. Xvivo Perfusion AB's value of 47.01 is 101.7% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #311 out of 416 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #311 out of 416 companies for EV-to-FCF. This places Xvivo Perfusion AB in the lower half of its industry. The industry median EV-to-FCF is 23.31. Xvivo Perfusion AB's value of 47.01 is 101.7% above this benchmark. While the company's 10-year median is 116.77 vs. the industry median of 23.31, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.31, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EV-to-FCF of 47.01 is 101.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EV-to-FCF is 47.01, which is 60% below median its own 10-year median of 116.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (FRA:3XV) is currently considered Significantly Undervalued. The stock's GF Value™ is €36.59, compared to a current price of €25.08 — trading 31.5% below its estimated fair value. The current EV-to-FCF is 47.01, which is 60% below median its 10-year median of 116.77 and 101.7% above the Medical Devices & Instruments industry median of 23.31. Xvivo Perfusion AB's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xvivo Perfusion AB (FRA:3XV), the current EV-to-FCF is 47.01 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (FRA:3XV) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of €25.08 is trading 31.5% below its estimated GF Value™ of €36.59.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for FRA:3XV:
EV-to-FCF: 47.01 (60% below median its 10-year median of 116.77)
GF Value™: €36.59 vs. price of €25.08 (31.5% below fair value)
Industry Position: 101.7% above the Medical Devices & Instruments median (#311 of 416)
No single metric tells the full story. See the FRA:3XV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
89GF Score
Get the complete analysis for FRA:3XV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3XV has been successfully added to your 
